ARQT Form 144: Insider Sale Notice for Vested Shares

Arcutis Biotherapeutics submitted a Form 144 notice dated 05/11/2026 reporting proposed sales related to vested restricted common stock.

Rhea-AI Filing Summary

Arcutis Biotherapeutics submitted a Form 144 notice dated 05/11/2026 reporting proposed sales related to vested restricted common stock. The filing lists a restricted stock vesting event dated 05/01/2026 and shows recent dispositions of 684 shares on 05/04/2026 and 6,287 shares on 03/02/2026.

This notice identifies the reporting person Patrick Burnett and provides addresses and dollar amounts tied to the recent dispositions; the filing documents a proposed sale process rather than completed market impact or company financial data.

Insights

Corporate Governance Analyst

Routine insider sale notice tied to vested restricted shares.

The Form 144 lists a restricted stock vesting dated 05/01/2026 and proposed sales by the reporting person. Recent reported dispositions include 684 shares (05/04/2026) and 6,287 shares (03/02/2026).

These filings are administrative disclosures of intended sales; their market significance depends on actual execution and scale versus total outstanding shares, which the excerpt does not state. Subsequent transaction notices or market filings would show execution details.

Key Figures

Form filed: 05/11/2026 Restricted stock vesting date: 05/01/2026 Disposition on 05/04/2026: 684 shares +3 more

6 metrics

Form filed 05/11/2026 Form 144 filing date

Restricted stock vesting date 05/01/2026 vesting date tied to proposed sale

Disposition on 05/04/2026 684 shares sold by reporting person on 05/04/2026

Disposition on 03/02/2026 6,287 shares sold by reporting person on 03/02/2026

Proceeds shown $16,149.65 dollar amount tied to 05/04/2026 disposition

Proceeds shown $158,319.86 dollar amount tied to 03/02/2026 disposition

Key Terms

Form 144, Restricted Stock Vesting, Proposed sale / Securities To Be Sold

3 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Vesting financial

"Common | 05/01/2026 | Restricted Stock Vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Proposed sale / Securities To Be Sold regulatory

"144: Securities To Be Sold"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does ARQT's Form 144 filed 05/11/2026 report?

The filing reports proposed sales tied to a restricted stock vesting event dated 05/01/2026. It lists recent dispositions of 684 shares on 05/04/2026 and 6,287 shares on 03/02/2026, and identifies reporting person Patrick Burnett.

Who is the reporting person named in the ARQT Form 144?

The notice names Patrick Burnett with an address in Westlake Village, CA. The filing provides contact/address details and links the reported proposed sales to his vested restricted common stock position.

Does the Form 144 confirm the sales were executed?

No, the Form 144 is a notice of proposed sale; it documents intended or planned dispositions tied to vesting. The excerpt shows prior dispositions on specific dates but does not itself prove execution of any remaining proposed sales.

What specific share amounts are disclosed in the filing?

The excerpt discloses 684 shares sold on 05/04/2026 for $16,149.65 and 6,287 shares sold on 03/02/2026 for $158,319.86. A restricted stock vesting date is 05/01/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/11/2026 - 04:44 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001741987
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Patrick Burnett
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	222	4673.1	125083374	05/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			222	05/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	05/04/2026	684	16149.65
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	03/02/2026	6287	158319.86

144: Remarks and Signature

Remarks
Date of Notice	05/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Patrick Burnett
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)